Test for COVID-19
Avicena laboratory offers a comprehensive test portfolio for COVID-19, including:
MOLECULAR REAL TIME PCR ТЕСТ FOR TRAVELING
Molecular test for SARS-CоV-2 detection 2.600,00 MKD
Ultra fast molecular PCR test for SARS-CоV-2 detection 5.200,00 MKD
(results in 1 hour)
The combination of the two types of tests gives a complete and realistic picture of what is happening in the human body, so that immunoassays and molecular tests are complementary and complement each other. Where the molecular tests detect the presence of the virus itself or even just a sequence of RNA from the virus, by measuring the concentration of antibodies, it is possible to see if the organism has been in contact with the virus and what the body's immune response is. in the fight against this virus.
IMPORTANT NOTICE!
- Taking samples for COVID-19 test is being performed only in laboratory in Municipality Taftalidze (07.00 -19.00h) and Tetovo (08.00 - 14.00h).
- The tests for COVID-19 can be scheduled every working day and Saturday on the following phone numbers:
071/278-529; 078/218-731; 071/269-623 and 072/319-850.
- The results from COVID-1`9 test are being issued within 24 hours. The result from the sampling done on Saturday afternoon, are being isued on Monday by 13.00h.
- The results from ultra-fast molecular PCR COVID-19 test are being issued within 1 hour.
Sample collection
-Nasopharyngeal / oropharingeal swab sample for PCR SARS-CоV-2 test
-Venous blood for antibody immunoassay test (IgM +IgA , IgG SARS-CоV-2 antobodies)
Real-time PCR (COVID-19) - swab sample
The molecular test is a golden standard in testing, because with the help of molecular techniques, the presence of the virus itself is detected, and even just a sequence of RNA on the virus itself. The test being performed in Avicena laboratory has the following features:
► Highly accurate and precise Real-time PCR for detection of SARS-CоV-2
► CE-IVD certified and validated for automated use
► Uniqe test that identifies the three viral genes, with an internal control included
► In accordance with the WHO, US CDC, Ch-CDC recommendations
QUANTITATIVE IMMUNOASSAY FOR IgM + IgA and IgG SARS-CоV-2 ANTIBODIES in blood
CE-IVD certified test, with high clinical sensitivity ans specificity.
Measurement of IgM, IgA, and IgG antibodies is important in:
- DIAGNOSIS IN EARLY PHASE OF THE DISEASE
The appearance of antibodies means that the organism has been in contact with the virus and the body's immune system has been activated. IgM and IgA antibodies usually occur first, about 5 to 7 days after contact with the virus, and IgG antibodies about 14 days after contact with the virus. By measuring the concentration of IgA antibodies, the clinical sensitivity of the test is further enhanced.
- ASYMPTOMATIC PATIENTS
People who do not have or have not had any symptoms while in contact with the virus will be identified.
- PATIENTS WITH CLINICAL SYMPTOMS AND NEGATIVE MOLECULAR TEST
There are cases when for several reasons, the molecular test may be falsely negative. In this way, the immunoassay will help solve many dilemmas.
- STAGING OF THE DISEASE
- PROGNOSTIC VALUE
There are clinical studies that suggest that significantly increased concentrations of both types of antibodies are associated with worse disease progression and worse outcome.
- FOLLOW-UP INFECTION IN THE PAST
Detection of IgG antibodies in a negative molecular test suggests that we may have been in contact with the virus in the past or that we may have experienced the infection without symptoms.
- SELECTION OF PLASMA DONORS
The concentration of antibodies in the blood of patients who have undergone the disease is crucial to selecting patients who are suitable donors of convalescent plasma to treat COVID-19 patients
Result interpretation*
|
IgM+IgA concentration |
IgG concentration |
INTERPRETATION |
|
negative |
negative |
Infection is excluded or the patient is in „window” period |
|
positive |
negative |
Early stage of infection |
|
positive |
positive |
Active phase of infection, late phase of infection or recovery |
|
negative |
positive |
Late phase of infection / past infection |
Avicena Laboratory, in conditions of global COVID-19 pandemic undertakes all necessary measures on a daily basis, in order to protect the health of employees, patient health and public health, in accordance with the guidelines of the Commission for Infectious Diseases at the Ministry of Health and WHO.
